Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults
This study has been suspended.
( Based on an interim data review, the DSMB concluded that the vaccine cannot be shown in this trial to prevent HIV infection or affect the course of the disease. )
Study NCT00413725.
Last updated on May 16, 2008.
Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
